Clopidogrel + Aspirin

The pairing of clopidogrel and aspirin, often referred to as dual antiplatelet therapy, is one of the most widely used strategies in cardiovascular medicine for preventing harmful blood clots ^[3]. Both drugs are antiplatelet agents, meaning they act on platelets rather than on the clotting proteins targeted by anticoagulants, but they do so through separate and complementary mechanisms, which is why they are frequently given together ^[1][2]. The combination is used both as two separate tablets taken together and, in some markets, as a single fixed-dose product ^[1].

Aspirin blocks an enzyme called cyclooxygenase inside platelets, which stops them from making thromboxane A2, a chemical messenger that recruits and activates other platelets ^[2]. Clopidogrel works further along the process, at the P2Y12 receptor that platelets use to respond to another activating signal, adenosine diphosphate ^[1]. By shutting down two different activation pathways at once, the combination applies a stronger brake on clot formation than either drug used on its own ^[1][2].

In heart disease, the combination is a cornerstone of care for acute coronary syndromes and for patients who receive a coronary stent, where it helps prevent the stent and nearby vessels from clotting off during the vulnerable weeks and months after the procedure ^[3]. A large randomised trial in acute coronary syndromes without ST-segment elevation found that adding clopidogrel to aspirin reduced the combined rate of cardiovascular death, heart attack and stroke, which helped establish the regimen as standard practice ^[3].

The combination has also become important in stroke prevention. Trials in people who had just experienced a minor ischaemic stroke or a high-risk transient ischaemic attack showed that a short course of clopidogrel plus aspirin, started within a day of symptoms, lowered the risk of a further stroke over the following weeks compared with aspirin alone ^[4][5]. Because the benefit is concentrated in the early period while the bleeding risk accumulates over time, this dual therapy is generally used for only a limited number of weeks in the stroke setting before stepping back to a single drug ^[5].

The chief drawback of combining two antiplatelet drugs is bleeding: across the major trials, clopidogrel plus aspirin consistently caused more major bleeding than aspirin alone, so the decision to use it, and for how long, balances the reduction in clotting events against this added hazard ^[3][4][5]. Both component drugs are inexpensive and widely available; aspirin is sold over the counter in many countries, while clopidogrel is a prescription medicine, and both appear individually on the World Health Organization Model List of Essential Medicines ^[1][2]. The duration of dual therapy is tailored to the individual and to the reason for treatment ^[3][5].

This is a prescription regimen and the main risk is bleeding, which rises when the two drugs are combined. Expect easier bruising, nosebleeds, and gum bleeding; the feared events are serious gastrointestinal or intracranial bleeds. Aspirin can irritate the stomach and trigger ulcers, and some people are aspirin-sensitive. Clopidogrel works less well in people who carry reduced-function CYP2C19 variants, and its activation can be blunted by strong CYP2C19 inhibitors such as omeprazole. Combining this regimen with anticoagulants, other NSAIDs, or SSRIs further raises bleeding risk, and it is usually paused before major surgery.

The pairing of clopidogrel with aspirin, known as dual antiplatelet therapy, grew directly out of the coronary stent era of the 1990s, when clinicians needed more complete platelet suppression to prevent clots forming on newly implanted stents. A succession of landmark trials defined its role; CURE in 2001 established the benefit of adding clopidogrel to aspirin in acute coronary syndromes, while CREDO and CLARITY extended the evidence to stenting and myocardial infarction.

Later, the CHANCE trial in 2013 and the POINT trial in 2018 showed that a short course of the combination reduces recurrent strokes when started soon after a minor ischemic stroke or transient ischemic attack. Together these studies made the two-drug regimen a standard of care after percutaneous coronary intervention and in acute coronary syndromes. The combination is a practice-defined regimen built from two individually established essential medicines rather than a single manufactured product.

Clopidogrel plus aspirin is regarded as a standard of care and one of the best-validated strategies in cardiovascular and cerebrovascular medicine. Its appeal lies in a clear pharmacological logic; the two drugs suppress platelet activation through entirely separate pathways, so together they leave fewer routes by which a platelet can be switched on and provide more complete protection than either alone.

It is the established regimen after coronary stent placement and in acute coronary syndromes, and short courses have proven benefit soon after minor stroke or transient ischemic attack. The honest counterweight, well recognized in guidelines, is that this fuller blockade also lowers the blood's ability to stop bleeding, so the duration of therapy is individualized to balance clot prevention against bleeding risk. Handled with that judgment, it is viewed as a highly effective, evidence-rich combination.